Drug intelligence / Profile preview

Bi-CAR-T

Development stage: Preclinical
Lead developer: Bio4t2
Modality: CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
Administration: Intravenous

Overview

Bi-CAR-T is a preclinical-stage bispecific chimeric antigen receptor T-cell (CAR-T) therapy developed by Bio4t2 for the treatment of solid tumors. The therapy is engineered to simultaneously target two distinct cell-surface antigens on tumor cells, a strategy intended to overcome the challenges of antigen heterogeneity and immune escape that often limit the efficacy of monospecific CAR-T therapies in solid malignancies. Bi-CAR-T is built using Bio4t2's proprietary PrismCore and Bio-Engine platforms and is currently progressing toward clinical trial application.

Other names: bispecific CAR-T

Beyond the preview

Go deeper on Bi-CAR-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bi-CAR-T.

Explore the full profile